Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials

Statistics in Medicine

Volumn 17, Issue 14, 1998, Pages 1563-1580

  Thall, Peter F ^a   Sung, Hsi Guang ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BAYES THEOREM; CLINICAL TRIAL; MONITORING; PHASE 2 CLINICAL TRIAL; SEQUENTIAL ANALYSIS;

ANTINEOPLASTIC AGENTS; BAYES THEOREM; CLINICAL TRIALS, PHASE II; DATA INTERPRETATION, STATISTICAL; HUMANS; MATHEMATICAL COMPUTING; MODELS, STATISTICAL; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 0032581447     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0258(19980730)17:14<1563::AID-SIM873>3.0.CO;2-L     Document Type: Article

References (36)

1. Thall, P. F., Simon, R. and Estey, E. H. 'Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes', Statistics in Medicine, 14, 357-379 (1995).
2. Thall, P. F. and Simon, R. 'Practical Bayesian guidelines for phase IIB clinical trials', Biometrics, 50, 337-349 (1994).
3. Thal, P. F. and Simon, R. 'A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials', Controlled Clinical Trials, 15, 463-481 (1994).
4. Lazaridis, E. and Gonin, R. 'Continuously monitored stopping boundary methodologies: The issues of sensitivity, association and trial suspension', Statistics in Medicine, 16, 1925-1941 (1997).
5. Gehan, E. A. 'The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent', Journal of Chronic Diseases, 13, 346-353 (1961).
6. Schultz, J. R., Nichol, F. R., Elfring, G. L. and Weed, S. L. 'Multiple stage procedures for drug screening', Biometrics, 29, 293-300 (1973).
7. Fleming, T. R. 'One sample multiple testing procedure for phase II clinical trials', Biometrics, 38, 143-151 (1982).
8. Chang, M., Therneau, T. and Wieand, H. S. 'Designs for group sequential phase II clinical trials', Biometrics, 43, 865-874 (1987).
9. Therneau, T., Wieand, H. S. and Chang, M. 'Optimal designs for a grouped sequential binomial test', Biometrics, 46, 771-781 (1990).
10. Simon, R. 'Optimal two-stage designs for phase II clinical trials', Controlled Clinical Trials, 10, 1-10 (1989).
11. Friedman, L. M., Furberg, C. D. and DeMets, D. L. Fundamentals of Clinical Trials, John Wright, PSG Ltd., Boston, 1981.
12. Workshop on Early Stopping Rules in Cancer Clinical Trials, Robinson College, Cambridge, U.K., 13-15 April, 1993 (R. L. Souhami and J. Whitehead, guest editors), Statistics in Medicine, 13, No 13/14 (1994).
13. DeMets, D. L. and Lan, K. K. G. 'Interim analysis: The alpha spending approach', Statistics in Medicine 13, 1341-1356 (1994).
14. Jennison, C. and Turnbull, B. W. 'Interim analyses: The repeated confidence interval approach, (with discusion)', Journal of the Royal Statistical Society, Series B, 51, 305-361 (1989).
15. Freedman, L. S. and Spiegelhalter, D. J. The assessment of subjective opinion and its use in relation to stopping rules for clinical trials', Statistician, 32, 153-160 (1983).
16. Freedman, L. S. and Spiegelhalter, D. J. 'Comparison of Bayesian with group sequential methods for monitoring clinical trials', Controlled Clinical Trials, 10, 357-367 (1989).
17. Spiegelhalter, D. J., Freedman, L. S. and Parmar, M. K. B. 'Bayesian approaches to randomized trials, (with discussion)', Journal of the Royal Statistical Society, Series A, 157, 357-416 (1994).
18. Berry, D. A. 'A case for Bayesianism in clinical trials (with discussion)', Statistics in Medicine, 12, 1377-1404 (1993).
19. Berry, D. A. 'Decision analysis and Bayesian methods in clinical trials', in Thall, P. F. (ed.), Recent Advances in Clinical Trial Design and Analysis, Kluwer, Boston, 1995, pp. 125-154.
20. Rosner, G. L. and Berry, D. A. 'A Bayesian group sequential design for a multiple arm randomized clinical trial', Statistics in Medicine, 14, 381-394 (1995).
21. Thall, P. F., Simon, R. and Estey, E. H. 'New statistical strategy for monitoring safety and efficacy in single-arm clinical trials', Journal of Clinical Oncology, 14, 296-303 (1995).
22. Bryant, J. and Day, R. 'Incorporating toxicity considerations into the design of two-stage phase II clinical trials', Biometrics, 51, 1372-1383 (1995).
23. Conaway, M. R. and Petroni, G. R. 'Bivariate sequential designs for phase II clinical trials', Biometrics 51, 656-664 (1995).
24. Conaway, M. R. and Petroni, G. R. 'Designs for phase II trials allowing for a trade-off between response and toxicity', Biometrics, 52, 1375-1386 (1996).
25. Jennison, C. and Turnbull, B. W. 'Group sequential tests for bivariate response: Interim analyses of clinical trials with both efficacy and safety endpoints', Biometrics, 49, 741-752 (1993).
26. Cook, R. J. and Farewell, V. T. 'Guidelines for monitoring efficacy and toxicity response in clinical trials', Biometrics, 50, 1146-1152 (1994).
27. Gibbons, J. D., Olkin, I. and Sobel, M. Selecting and Ordering Populations: A New Statistical Methodology, Wiley, New York, 1977.
28. Bechhofer, R. E., Santner, T. J. and Goldsman, D. Design and Analysis of Experiments for Statistical Selection, Screening and Multiple Comparisons, Wiley, New York, 1995.
29. Thall, P. F., Simon, R. and Ellenberg, S. S. 'Two stage selection and testing designs for comparative clinical trials', Biometrika, 75, 303-310 (1988).
30. Thall, P. F., Simon, R. and Ellenberg, S. S. 'A two-stage design for choosing among several experimental treatments and a control in clinical trials', Biometrics, 45, 537-547 (1989).
31. Schaid, D. J., Wieand, H. S. Therneau, T. M. 'Optimal two-stage screening designs for survival comparisons', Biometrika, 77, 507-513 (1990).
32. Simon, R., Wittes, R. E. and Ellenberg, S. S. 'Randomized phase II clinical trials', Cancer Treatment Reports, 69, 1375-1381 (1985).
33. Thall, P. F. and Estey, E. H. 'A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation', Statistics in Medicine, 12, 1197-1211 (1993).
34. Thall, P. F. and Simon, R. 'Incorporating historical data in planning Phase II clinical trials', Statistics in Medicine, 9, 215-228 (1990).
35. Thall, P. F. and Russell, K. E. 'A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials'. Biometrics (1998) to appear.
36. Heitjan, D. F. 'Bayesian interim analysis of phase II cancer clinical trials', Statistics in Medicine, 16, 1791-1802 (1997).